Drugs / RUXOTEMITIDE
RUXOTEMITIDE
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01986426 | Nov 2013 → Apr 2018 | head and neck cancer, lymphoma, melanoma, triple-negative breast carcinoma | Lytix Biopharma AS | Completed | No outcome recorded |
| Phase 1 | NCT01223209 | Aug 2010 → Dec 2011 | carcinoma | Lytix Biopharma AS | Completed | No outcome recorded |
| Phase 1 | NCT01058616 | Jan 2010 → Jan 2013 | — | Lytix Biopharma AS | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06651151 | Nov 2024 → May 2026 overdue | melanoma | Oslo University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04796194 | Jun 2021 → Feb 2025 | metastatic melanoma | Lytix Biopharma AS | Completed | No outcome recorded |
| Phase 2 | NCT03725605 | Dec 2018 → Jul 2021 | soft tissue sarcoma | Lytix Biopharma AS | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RUXOTEMITIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297628 ↗ |
| Known as | Kkwwkkw-.beta.-phenyl-fk-nh2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297628 ↗ |
| Known as | Kkwwkkwdipk-nh2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297628 ↗ |
| Known as | LTX-315 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04796194 ↗ |
| Known as | Oncopore | “LTX-315 (Oncopore™)” NCT01058616 ↗ |
| Known as | Ruxotemitida | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297628 ↗ |
| Modality | Peptide | “LTX-315 a lytic-peptide that has shown effect in animal models to kill cancer tumours” NCT01058616 ↗ |
| Route | Other | “LTX-315 injected directly into transdermally accessible tumours” NCT01058616 ↗ |